翰思艾泰生物：专注肿瘤免疫创新疗法的生物科技公司通过港交所聆讯，或很快香港上市

Group 1 - The core point of the article is that Hansai Aitai Biopharmaceutical Technology (Wuhan) Co., Ltd. is planning to list on the Hong Kong Stock Exchange, with ICBC International and CITIC Securities as the exclusive sponsors for the listing [1] - The funds raised from the IPO will primarily be used for the research and development of core product HX009, as well as other key products HX301 and HX044, and for commercialization and business development activities [1] - The company has developed a product portfolio since 2016, including one core product and nine other pipeline candidates, focusing on oncology and autoimmune diseases [2] Group 2 - The core product HX009 is a self-developed anti-PD-1/SIRPα dual-function antibody fusion protein, which has completed Phase I clinical trials in Australia and China, and is currently undergoing multiple Phase II clinical studies in China [2] - The company also has two major products, HX301 (a multi-target kinase inhibitor) and HX044 (a CTLA-4/SIRPα dual-function fusion protein), that are in clinical stages, along with several preclinical candidates aimed at addressing unmet medical needs in the global market [2]